GLP-1 RA with Chemotherapy for Metastatic Pancreatic, Colorectal, or Liver Cancer
This study is looking at the safety and how well a drug called semaglutide (a GLP-1 Receptor Agonist, or GLP-1 RA) works when given with standard chemotherapy for people with metastatic pancreatic, colorectal, or liver (hepatocellular) cancer. Doctors want to see if adding semaglutide, which is often used for diabetes and weight loss, is safe and effective when combined with cancer treatments. You might be able to join if you have one of these cancers that has spread and cannot be cured by surgery. The main goal is to track any side effects from semaglutide or its interaction with chemotherapy for up to 6 months, or until your disease gets worse. This study is currently unclear about its recruitment status and plans to enroll 30 participants.
- Study design
- This is an interventional study, meaning participants will receive a specific treatment. It is not specified if it's randomized or blinded, and aims to enroll 30 participants.
- What's involved
- Participants will receive weekly injections of semaglutide for 6 months. The dose of semaglutide will gradually increase every 4 weeks based on how well it's tolerated.
- Compensation
- Not stated in the trial record.
- Follow-up
- Safety will be measured for up to 6 months or until the disease progresses, whichever comes first.
AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.
NCT07627191
GLP-1 RA Plus SOC Treatment in First-line, Metastatic Pancreatic, Colorectal, or Hepatocellular Cancer
Not Yet Recruiting
EARLY_PHASE1Ages 18–99InterventionalTreatmentUniversity of ArizonaInvestigator-initiated
~30 participants
Updated 2026-07-02 on ClinicalTrials.gov
What's tested:GLP1-RA (semaglutide)
At a glance
Recruiting sites
0 of 1 listed site is recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
Incidence of Treatment Emergent Adverse Events [Safety] attributed to GLP1-RA and/or its interaction with chemotherapy
Measured over Up to 6 months or at time of disease progression, whichever comes first
Conditions
Where it's being run
1 sites across 1 statesArizona1
Study leadership
- Aaron J Scott, MD · PRINCIPAL_INVESTIGATOR · University of Arizona
Who to contact
Opens a ready-to-send draft in your own email app — review before sending.
Do you actually qualify for this trial?
Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.
Eligibility criteria
Inclusion
Histological or cytological diagnosis of pancreatic adenocarcinoma or colorectal adenocarcinoma. Previous tumor tissue testing is acceptable. Please refer to the "additional HCC cohort criteria" below.
The subject has disease that is not amenable to curative-intent management (e.g., oligometastatic disease)
Measurable disease per RECIST v1.1 as determined by the investigator
Patients must be appropriate candidates for first-line, SOC treatment.
SOC treatment as defined by NCCN® guidelines or institutional standard is allowable, however, options restricted to:
Colorectal: FOLFOX or FOLIFIRI +/- bevacizumab
Pancreatic: mFOLFIRINOX
HCC: Tremelimumab/Durvalumab
Patients are eligible who received prior perioperative chemotherapy for curative intent treatment and recurred ≥ 6 months since last dose of chemotherapy.
≥ 18 years old on day of consent
Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1
Adequate archival frozen or fixed tissue available from primary or metastatic site for genotypic analysis (at least 15 unstained slides and/or tumor block)
Adequate hematologic and organ function laboratory values as follows:
The ANC ≥ 1500/mm3 without colony stimulating factor support;
Platelets ≥ 75,000/mm3;
Hemoglobin ≥ 9 g/dL;
Bilirubin ≤ 1.5 ´ the ULN. For subjects with known Gilbert's disease, bilirubin ≤ 3.0 mg/dL;
Serum albumin ≥ 2.8 g/dl;
ALT and AST ≤ 3.0 ´ ULN;
Serum creatinine ≤ 1.5 ´ ULN or creatinine clearance (CrCl) ≥ 40 mL/min. For creatinine clearance estimation, the Cockcroft and Gault equation should be used:
Male: CrCl (mL/min) = (140 - age) × wt (kg) / (serum creatinine × 72);
Female: Multiply above result by 0.85;
The subject is capable of understanding and complying with the protocol requirements and has signed the informed consent document
Sexually active subjects (men and women) must agree to use medically accepted barrier methods of contraception (eg, male or female condom) during the study and for 4 months after the last dose of study drug(s), even if oral contraceptives are also used. All subjects of reproductive potential must agree to use both a barrier method and a second method of birth control or practice abstinence during the study and for 4 months after the last dose of study drug(s);
Histologically or radiologically confirmed hepatocellular carcinoma (per AASLD/EASL criteria)
Unresectable or advanced HCC not amenable to curative surgery or locoregional therapy.
Barcelona Clinic Liver Cancer (BCLC) stage B or C.
Child-Pugh Score Class A; or Child-Pugh Class B7 or B8 at discretion of treating physician
Patients with HBV infection, characterized by positive hepatitis B surface antigen (HBsAg) and/or hepatitis B core antibodies (anti-HBcAb) with detectable HBV deoxyribonucleic acid (DNA) (≥10 IU/mL or above the limit of detection per local or central lab standard), must be treated with antiviral therapy, as per institutional practice to ensure adequate viral suppression (HBV DNA \<2000 IU/mL) before enrolment. Patients must remain on antiviral therapy for the duration of their participation in the EAP and for 6 months after the last dose of EAP medication. Patients who test positive for anti-hepatitis B core (HBc) with undetectable HBV DNA (\<10 IU/mL or under the limit of detection per local or central lab standard) do not require anti-viral therapy before enrolment. These participants will be tested at every cycle to monitor HBV DNA levels and initiate anti-viral therapy if HBV DNA is detected (≥10 IU/mL or above the limit of detection per local or central lab standard). HBV DNA detectable patients must initiate and remain on anti-viral therapy for time they are on the EAP and for 6 months after the last dose of EAP medication.
Patients with HCV infection must have confirmed diagnosis of HCV characterized by the presence of detectable HCV ribonucleic acid (RNA) or anti-HCV antibody upon enrolment (management of this disease is per local institutional practice).
Exclusion
The subject has received cytotoxic chemotherapy (including investigational cytotoxic chemotherapy) or biologic agents (eg, cytokines or antibodies) for metastatic and/or unresectable disease.
BMI \< 25 kg/m2
For colorectal cancer only - Microsatellite instability high (MSI-H) or mismatch repair deficient (dMMR) tumors.
For colorectal cancer only - BRAF V600E mutant tumors.
A personal or family history of medullary thyroid cancer (MTC) or Multiple Endocrine Neoplasia syndrome type 2 (MEN2).
A prior hypersensitivity reaction to semaglutide or any of the excipients in WEGOVY®. Serious hypersensitivity reaction, including anaphylaxis and angioedema, have been reported with WEGOVY®.
Cachexia
Subjects on insulin.
Subjects with a history of diabetic retinopathy
Known brain metastases or cranial epidural disease unless adequately treated with radiotherapy and/or surgery (including radiosurgery) and stable for at least 4 weeks before the first dose of study treatment. Eligible subjects must be neurologically asymptomatic and without corticosteroid treatment at the time of the start of study treatment
The subject has uncontrolled, significant intercurrent or recent illness including, but not limited to, the following conditions:
For patients being considered for bevacizumab (or bevacizumab biosimilar) only:
Concurrent uncontrolled hypertension defined as sustained blood pressure (BP) \> 150 mm Hg systolic or \> 100 mm Hg diastolic despite optimal antihypertensive treatment within 7 days of the first dose of study treatment;
thromboembolic event requiring therapeutic anticoagulation (Note: subjects with a venous filter (eg, vena cava filter) within 6 months before the first dose of study treatment.
Any of the following within 6 months before the first dose of study treatment:
unstable angina pectoris;
clinically-significant cardiac arrhythmias;
stroke (including transient ischemic attack (TIA), or other ischemic event);
myocardial infarction;
GI disorders particularly those associated with a high risk of perforation or fistula formation including:
Unresolved abdominal fistula, GI perforation, bowel obstruction, intra-abdominal abscess.
Uncontrolled nausea, vomiting, or abdominal pain.
Other clinically significant disorders that would preclude safe study participation
Major surgery within 8 weeks before the first dose of study treatment. Subjects with clinically relevant ongoing complications from prior surgery are not eligible.
Females who are known or suspected to be pregnant or lactating. Women of childbearing potential must have a negative serum pregnancy test result within screening.
Female patients planning on becoming pregnant while on study.
Male subjects with a pregnant partner who are unwilling to practice abstinence or use a condom during treatment.
Male subjects unwilling to abstain from donating sperm during treatment.
Inability to comply with self-administration of GLP-1 RA subcutaneous injections.
Subject has known sensitivity to any of the products or components to be administered during dosing.
Concurrent use of other semaglutide containing products or any other GLP-1 receptor agonist.
Diagnosis of another malignancy within 2 years before the first dose of study treatment, except for superficial skin cancers, or localized, low grade tumors deemed cured and not treated with systemic therapy.
Subject likely to not be available to complete all protocol-required study visits or procedures and/or to comply with all required study procedures to the best of the subject and investigator's knowledge.
History or evidence of any other clinically significant disorder, condition or disease that in the opinion of the investigator, if consulted, would pose a risk to subject safety or interfere with the study evaluation, procedures, or completion.
Child-Pugh Score Class B9; or Child-Pugh Class C
Radiotherapy treatment to more than 30% of the bone marrow or with a wide field of radiation within 28 days of the first dose of EAP treatments.
History of allogenic organ transplantation (e.g., liver transplant).
History of hepatic encephalopathy within the past 12 months or requirement for medications to prevent or control encephalopathy (e.g., no lactulose, rifaximin, etc if used for purposes of hepatic encephalopathy.
Clinically meaningful ascites, defined as any ascites requiring non-pharmacologic intervention (e.g., paracentesis) to maintain symptomatic control, within 2 months before the first EAP treatment dose. Patients on stable doses of diuretics for ascites for ≥2 months are eligible.
Patients with main portal vein thrombosis (i.e., thrombosis in the main trunk of the portal vein, with or without blood flow) on baseline imaging.
Active or previously documented autoimmune or inflammatory disorders (including inflammatory bowel disease \[e.g., colitis or Crohn's disease\], diverticulitis \[except for diverticulosis\], systemic lupus erythematosus, Sarcoidosis syndrome, or Wegener syndrome \[granulomatosis with polyangiitis, Graves' disease, rheumatoid arthritis, hypophysitis, uveitis, etc\]). Patients without active disease in the last 5 years are excluded unless discussed with the Treating Physician and considered appropriate for EAP participation. The following are exceptions to this criterion:
Patients with vitiligo or alopecia
Patients with hypothyroidism (e.g., following Hashimoto syndrome) stable on hormone replacement
Any chronic skin condition that does not require systemic therapy
Patients with celiac disease controlled by diet alone
Patients co-infected with HBV and HCV, or co-infected with HBV and hepatitis D virus (HDV). HBV positive (presence of HbsAg and/or anti-HBcAb with detectable HBV DNA); HCV positive (presence of anti-HCV antibodies); HDV positive (presence of anti-HDV antibodies).
Known fibrolamellar HCC, sarcomatoid HCC, or mixed cholangiocarcinoma and HCC.
History of active primary immunodeficiency.
Current or prior use of immunosuppressive medication within 14 days before the first dose of EAP treatment. The following are exceptions to this criterion:
Intranasal, inhaled, topical steroids, or local steroid injections (e.g., intra-articular injection)
Systemic corticosteroids at physiologic doses not to exceed 10 mg/day of prednisone or its equivalent
Steroids as pre-medication for hypersensitivity reactions (e.g., CT scan pre-medication)
Receipt of live attenuated vaccine within 30 days before first dose of treatment. Note: patients, if enrolled, should not receive live vaccine while receiving study treatment, and up to 30 days after the last dose of study treatment.
Previous randomization or treatment in a previous durvalumab and/or tremelimumab clinical study regardless of treatment arm assignment.
Patients who have received anti-PD-1, anti-PD-L1, or anti-CTLA-4 before the first dose of EAP treatment.
What this trial measures
- Incidence of Treatment Emergent Adverse Events [Safety] attributed to GLP1-RA and/or its interaction with chemotherapyUp to 6 months or at time of disease progression, whichever comes first
Safety is defined as the incidence of grade ≥3 adverse events (AEs) as defined by CTCAE v5.0, attributed to GLP-1 RA and/or its interaction with chemotherapy